Leerink Partners analyst Roanna Ruiz maintained a Buy rating on Aligos Therapeutics (ALGS – Research Report) on April 4. The company’s shares closed last Tuesday at $2.14, close to its 52-week low of $1.99.
According to TipRanks.com, Ruiz has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -16.7% and a 48.0% success rate. Ruiz covers the Healthcare sector, focusing on stocks such as Enanta Pharmaceuticals, Xeris Pharmaceuticals, and Atea Pharmaceuticals.
Currently, the analyst consensus on Aligos Therapeutics is a Moderate Buy with an average price target of $8.33.
The company has a one-year high of $34.31 and a one-year low of $1.99. Currently, Aligos Therapeutics has an average volume of 564.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH).
Read More on ALGS:
- Cerence (CRNC) Gets a Sell Rating from RBC Capital
- Leerink Partners Remains a Buy on Castle Biosciences (CSTL)
- Guardant Health (GH) Gets a Buy Rating from Leerink Partners
- RBC Capital Believes ARC Resources (AETUF) Still Has Room to Grow
- RBC Capital Maintains Their Hold Rating on Crew Energy (CWEGF)